Rezq Bio

Executive Summary

Rezq Bio is a San Diego-based biotechnology company pioneering a novel dendritic cell therapy platform to treat autoimmune and inflammatory diseases, with an initial focus on Type 1 Diabetes (T1D). Unlike traditional systemic immunosuppression, Rezq’s approach targets regional inflammation locally, aiming to restore immune tolerance with minimal side effects across all disease stages. Founded in 2021 and currently in Phase 1 development, the company seeks to address a significant unmet need in T1D, where over 1.5 million Americans require lifelong insulin management. Despite the lack of disclosed funding or valuation data, Rezq’s differentiated mechanism and early clinical stage position it as a high-risk, high-reward candidate in the cell therapy space. The company’s platform is adaptable to other autoimmune indications, offering potential expansion opportunities if proof-of-concept is established.

Upcoming Catalysts (preview)

• Q1 2027Phase 1 interim safety and biomarker data release for T1D candidate40% success
• Q2 2027Series A or Series B financing round50% success
• Q4 2026FDA orphan drug designation (ODD) for lead T1D therapy70% success